Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

In a remarkable turn of events within the pharmaceutical industry, Eli Lilly's tirzepatide has overtaken Merck's Keytruda to become the world’s best-selling medicine. This shift highlights not only ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the ...

Eli Lilly LLY reported 54% revenue growth in the third quarter as its diabetes and obesity drug tirzepatide (Mounjaro/Zepbound) continued to gain share globally, and management raised top- and ...